Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
45 hedge funds and large institutions have $50M invested in Merrimack Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 3 closing their positions.
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
13% more funds holding
Funds holding: 40 → 45 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less capital invested
Capital invested by funds: $55.2M → $50M (-$5.16M)
32% less call options, than puts
Call options by funds: $669K | Put options by funds: $991K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$257K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$207K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$200K |
| 4 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$182K |
| 5 |
Bank of New York Mellon
New York
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.02M |
| 2 |
Two Sigma Advisers
New York
|
-$442K |
| 3 |
Two Sigma Investments
New York
|
-$362K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$224K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.57K |
MACK Hedge Fund Activity: Q1 2021 in Review
45 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2021, worth a combined $50M — down 9.4% from $55.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MACK positions and 3 closed out — a net gain of 5 holders — while 17 added to existing stakes and 5 trimmed.
The largest buyer was Marshall Wace, adding an estimated $257K. The largest seller was Nantahala Capital Management, cutting an estimated $1.02M.
- 45 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2021, up from 40 in Q4 2020.
- Funds reported $50M of Merrimack Pharmaceuticals, Inc. stock for Q1 2021, down 9.4% quarter-over-quarter.
- 8 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2021 and 3 closed out, a net change of +5 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2021 was Marshall Wace, an estimated $257K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2021 was Nantahala Capital Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2021.